Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival AbbVie in garnering...
10 November 2021 Regional News AbbVie | Amgen
Continue Reading →
Regional News

Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share

Biohaven's migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and prevent migraines. Now, the comp...
6 October 2021 Regional News anti-CGRP | Biohaven
Continue Reading →
Regional News

Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users

Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie—thanks to Nurtec ODT's dual acute-plus-prevention nod and an aggressive digital...
25 August 2021 Regional News Biohaven | dual-migraine
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte